Appropriateness of the treatment of fatigued patients with stage IV cancer
Cette étude de cohorte menée auprès de 160 participants (âge médian : 67 ans, 40 cas de cancer du poumon, 40 cas de cancer du sein, 40 cas de cancer du colon, 40 cas de cancer de la prostate) évalue l'utilisation des traitements de la fatigue chez des patients atteints d'un cancer de stade IV
Background Fatigue among patients with cancer is prevalent, disabling, and treatable. While fatigue management guidelines have been in place for a decade, their use remains unclear. Methods We surveyed 160 patients with stage IV lung (40), breast (40), colon (40), and prostate (40) cancer who reported moderate to severe fatigue (i.e., > 5 of 10 on an 11-point numerical rating scale). Participants were queried about receipt of treatments in fatigue management domains emphasized in the National Comprehensive Cancer Network guidelines: general management strategies, activity enhancement, psychosocial strategies, and pharmaceuticals. Results The cohort was half male, had a mean age of 67, and reported an average fatigue rating of 6.4. Participants reported treatment or receipt of specific guidance in the fatigue management domains as follows: general management strategies 16.8 %, activity enhancement 11.9 %, psychosocial strategies 9.9 %, and pharmaceuticals 37.3 %. Fatigue > 7 of 10 increased the likelihood of instruction in activity enhancement but no other domain. Conclusion The low rates of guideline-congruent treatment reported here are concerning, particularly as better validated behavioral treatments were the least prescribed.